Results of the phase 2 diagnostic investigator-initiated trial of 64Cu SAR-Bombesin in prostate cancer (BOP) have shown the novel theranostic radiopharmaceutical can detect lesions in men with biochemically recurrent (BCR) prostate cancer that are either negative or equivocal on prostate-specific membrane antigen positron emission tomography (PSMA PET). ...
mCRPC
Advertisement
Latest News
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel.
The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate.
Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors.
Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
